Despite the milestone, funding remains far short of what's needed, according to a new report.
The shorter 6-month regimen could save enough to supply 400,000 people with almost a year's worth of treatment.
The findings suggest the drug could be part of a shorter and simpler tuberculosis treatment regimen.
A study today in BMC Medicine highlights the toll that the COVID-19 pandemic has taken on the diagnosis of tuberculosis (TB) in high-burden countries, particularly in vulnerable populations.
A clinical trial conducted in seven countries found that two shortened, bedaquiline-containing regimens had superior efficacy in treating rifampicin-resistant tuberculosis (TB) compared with a 9-month injectable-containing regimen, with fewer cases of hearing loss, investigators reported today in The Lancet.
WHO officials say the COVID-19 pandemic's impact on essential TB services has reversed years of progress.
A systematic review and meta-analysis today in Vaccine finds no link between COVID-19 vaccines and infertility in men or women.
Researchers at a Rome hospital analyzed 29 studies from China, Israel, Italy, Russia, Turkey, Canada, and the United States until Jun 8, 2022. Of the studies, 13.8% were deemed of poor quality, 58.6% were of moderate quality, and 27.6% were of good quality.
A relatively simple 6-month regimen cured 90% or more of patients who have MDR-TB.
A randomized clinical trial in Niger found that mass distribution of azithromycin to preschool-aged children was no more effective at reducing incidence of trachoma than placebo, researchers reported today in JAMA Network Open.
The process generates a list of antibiotics to which the infection is susceptible.
